Since CD123 is just overexpressed and not mutated in hematological malignancies, its therapeutic targeting must involve the use of agents that specifically interact with this receptor, such as its natural ligand IL3, or monoclonal antibodies that either vehiculate cytotoxic agents into CD123+ leukemic cells and induce their killing or trigger an immune response, activating the immune system. Here, IL3RA is linked to hematologic disorder.